title: New insights into the molecular pathogenesis of langerhans cell histiocytosis.
abstract: Langerhans cell histiocytosis (LCH) is a rare proliferative disorder characterized by an accumulation of cells sharing the major phenotypic features of cutaneous Langerhans cells. Given its variable clinical evolution, ranging from self-limiting lesions to multisystemic forms with a poor prognosis, in the last decades it has been debated whether LCH might not have a neoplastic rather than an inflammatory nature. However, although the fundamental events underlying the pathogenesis of LCH are still elusive, recent advances have strikingly improved our understanding of the disease. In particular, the identification of multiple interplays between LCH cells and their tumor microenvironment, along with the recognition of the lesional cytokine storm as a key determinant of LCH progression, has substantiated new opportunities for devising targeted therapeutic approaches. Strikingly, the detection of the rapidly accelerated fibrosarcoma isoform B(V600E) gain-of-function mutation as a genetic alteration recurring in more than 50% of patients has fueled the paradoxical picture of LCH as a tumor of the antigen-presenting cells that can evade rejection by the immune system. Thus, new evidence regarding the ontogeny of LCH cells, as well as a better understanding of the putative immune system frustrating strategy in LCH, may help to define the precise pathogenesis.
authors.affiliation: Department of Biomedical Sciences and Human Oncology, University of Bari Aldo Moro, Bari, Italy.
authors.forename: Francesca M
authors.initials: FM
authors.lastname: Rizzo
authors.forename: Mauro
authors.initials: M
authors.lastname: Cives
authors.forename: Valeria
authors.initials: V
authors.lastname: Simone
authors.forename: Franco
authors.initials: F
authors.lastname: Silvestris
mesh_terms: D006646:Histiocytosis, Langerhans-Cell / Q000209:etiology* / Q000473:pathology*; D006801:Humans
keywords: BRAF kinases; Bone marrow; Cancer microenvironment; Interleukin-17; Langerhans cell histiocytosis; Vemurafenib